UK Needs ‘National Strategy’ To Fix Cell And Gene Industry Skill Gaps
Executive Summary
Health policy researchers have called on the UK government to address cell and gene therapy workforce gaps at a national level, warning that training academies run by “well-funded” pharma firms risk “undermining” and fragmenting the industry as a whole.
You may also be interested in...
UK Industry ‘Struggling’ With Skill Gaps In AI, Robotics & Data Analytics
A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.
Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.
Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?
A report comparing the health technology assessment methods used in nine European countries, Australia and Canada found that England has the most favorable reimbursement landscape for gene therapies – but outlined several areas for improvement across the board.